×
We recently upgraded the website!  If you run into any issues, please Contact Us.  We'd also love to hear your feedback!  Enjoy exploring the new site!

rf-fullcolor.png

 

April 28, 2026
by Jason Scott

Recon: Supreme Court to consider skinny labeling case; Opioid settlement likely after Purdue Pharma sentencing

RegulatoryRecon_440x248.jpg
In Focus: US
  • Supreme Court to hear case about ‘skinny labeling’ and generic access (STAT)
  • New U.S. recommendation on hepatitis B vaccine will have dire consequences, studies project (STAT)
  • Updated: FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug now owned by Amgen (Endpoints)
  • Purdue Pharma to be sentenced, paving way for opioid settlement (Reuters)
  • US FDA Unveils Real-Time Clinical Trials To Speed Data Review (Pink Sheet)
In Focus: International
  • Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spending (Endpoints)
  • Exclusive: Ghana rejects proposed US health aid deal, citing data concerns (Reuters)
  • UK Must Tackle ‘Variation’ In Clinical Trial Set Up Times, Says O’Shaughnessy (Pink Sheet)
  • Regeneron Seeks EU Fast-Track Review For Hearing Loss Gene Therapy Following Swift US Approval (Pink Sheet)
Pharma & Biotech
  • Eli Lilly enlists AI startup for next-generation gene editors (STAT)
  • Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy (STAT)
  • Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel (Endpoints)
  • BeOne joins the VEGF competition, but with a trispecific antibody (Endpoints)
  • Incyte claims double Phase 3 win in vitiligo, will file for approval (Endpoints)
  • AI keeps tackling harder targets in protein design, latest Adaptyv contest shows (Endpoints)
  • Lilly strikes second partnership this year for recombinase-based gene editing (Endpoints)
  • Galapagos spinout Coultreon raises $125M for new take on SIK inhibition (Endpoints)
  • Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (Reuters)
  • Centene raises 2026 profit forecast on improving cost controls (Reuters)
  • With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms (Fierce Pharma)
Medtech
  • Zimmer Biomet CFO departs for new job (MedTech Dive)
  • Thermo Fisher inks $1.1B deal to sell microbiology unit to Astorg (MedTech Dive)
  • Medtronic reports data breach on corporate IT systems (MedTech Dive)
  • Medtronic Catheter Shows Promise in Treating Dangerous Heart Disorder (MedTech Insight)
Food & Nutrition
  • Argentina has 'serious' concerns after soymeal shipments withdrawn in EU over GMO breaches (Reuters)
  • Salmonella outbreak spreads across Europe (Food Safety News)
  • Bill would give FDA permission to provide states with food safety information (Food Safety News)
Government, Regulatory & Legal
  • Devoted Health’s 2025 revenue slips in turbulent Medicare Advantage market (Endpoints)
  • Not So Fast: When “RAPID” Isn’t Enough (FDA Law Blog)

Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.

A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.